Local and systemic growth regulators control normal bone formation. Of these, transforming growth factor-beta (TGF-beta) appears to have a critical and complex role in bone health and disease. Specific changes in TGF-beta receptor (TbetaR) levels occur on bone cells in response to important stimulators and inhibitors of osteogenic cell activity in vitro. Moreover, TGF-beta independently stimulates and inhibits several aspects of osteoblast activity, often in phenotype-related ways. These observations predict that gain or loss of specific TbetaRs can determine whether and how osteoblasts respond to TGF-beta exposure. In order to avoid detrimental effects by inappropriate expression of TbetaRs and to focus TGF-beta activity more accurately on bone cells, mechanisms that control TbetaR synthesis and signaling must be resolved. Studies in this proposal will continue to define genomic and biochemical elements that regulate these events. TbetaR gene promoters will be dissected by reporter gene and gel shift analyses, and by deletions and mutations to define cis- and trans-acting elements that regulate TbetaR gene expression. TbetaR protein and mRNA levels will be measured by radioligand binding, Western blot and RNase protection analyses. Interactions among individual TbetaRs will be examined by immunoprecipitation and Western analyses. Downstream effects on TGF-beta activity will be assessed on cell replication and matrix protein synthesis, and by assays and forced expression of genes that relate to the expression or the activity of individual TbetaRs. These parameters will be studied in response to well-defined local and systemic bone growth regulators. Studies in Aim I will define regulatory elements in the TbetaRI gene promoter that repress its expression, with an emphasis on Runx-sensitive cis- and trans-acting elements. Results will be extended to other Runx-sensitive gene targets that may be repressed in a similar way. Studies in Aim 2 will concentrate on the TbetaRII gene promoter, in particular on E box binding proteins that appear to control TbetaRII expression during osteoblast differentiation. They will also assess the possibility of co-ordinate control with TbetaRIII, and extend to a limited number of E box sensitive genes with relevance to bone. Studies in Aim 3 will define functional aspects of TbetaRlll expression in osteoblasts. They will examine interactions between TbetaRIII and its PDZ-domain binding cofactor GIPC, and the effect of TbetaRIII glycosylation on native and hormone-induced changes in TbetaR multimer complex formation and stability. Due to the importance of TGF-beta in bone metabolism, studies like these that initiate with TbetaR expression on osteoblasts may continue to define new molecular targets that could be used to focus and enhance bone growth and repair.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR039201-17
Application #
6909841
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Program Officer
Sharrock, William J
Project Start
1988-09-01
Project End
2008-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
17
Fiscal Year
2005
Total Cost
$356,839
Indirect Cost
Name
Yale University
Department
Surgery
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
McCarthy, Thomas L; Centrella, Michael (2015) Prostaglandin dependent control of an endogenous estrogen receptor agonist by osteoblasts. J Cell Physiol 230:1104-14
McCarthy, Thomas L; Centrella, Michael (2015) Androgen receptor activation integrates complex transcriptional effects in osteoblasts, involving the growth factors TGF-? and IGF-I, and transcription factor C/EBP?. Gene 573:129-40
McCarthy, Thomas L; Yun, Zhong; Madri, Joseph A et al. (2014) Stratified control of IGF-I expression by hypoxia and stress hormones in osteoblasts. Gene 539:141-51
McCarthy, Thomas L; Kallen, Caleb B; Centrella, Michael (2011) ?-Catenin independent cross-control between the estradiol and Wnt pathways in osteoblasts. Gene 479:16-28
McCarthy, Thomas L; Centrella, Michael (2010) Novel links among Wnt and TGF-beta signaling and Runx2. Mol Endocrinol 24:587-97
Sankar, S; Mahooti-Brooks, N; Bensen, L et al. (1996) Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 97:1436-46
Sigel, A V; Centrella, M; Eghbali-Webb, M (1996) Regulation of proliferative response of cardiac fibroblasts by transforming growth factor-beta 1. J Mol Cell Cardiol 28:1921-9
Sankar, S; Mahooti-Brooks, N; Centrella, M et al. (1995) Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J Biol Chem 270:13567-72